The Effect of a Single Dose of Methylphenidate on Attention in Children and Adolescents with ADHD and Comorbid Oppositional Defiant Disorder

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Aug 12

PMID 39133690

Authors

Barbara DAiello

Silvia Di Vara

Pietro De Rossi

Stefano Vicari

Deny Menghini

Affiliations

Soon will be listed here.

Abstract

The co-occurrence Oppositional Defiant Disorder (ODD) in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) has been associated to difficulties in regulating adverse states, elevated functional impairment, deficits in Executive Functions and high risk for psychopathology. Recent studies have shown that ODD is a negative predictor of a positive response to methylphenidate (MPH) treatment for ADHD symptoms in children and adolescents and that patients with a diagnosis of comorbid ADHD and ODD are less likely to respond favorably to pharmacological treatment with MPH. We conducted a naturalistic study to understand the clinical characteristics of drug-naïve children and adolescents with ADHD that influence the response to MPH by measuring the effect on attention. Specifically, we investigated whether a single dose of MPH differently affects the performance of 53 children and adolescents with ADHD with or without ODD comorbidity. In addition, participant characteristics such as symptom severity, functional impairment, and associated behavioral and emotional symptoms at baseline were examined to better understand what aspects affect the response to MPH. We found that a single dose of MPH improved the attention of children and adolescents with ADHD without ODD more than those with comorbid ADHD and ODD, resulting in reduced reaction times. Our findings indicated that children and adolescents with comorbid ADHD and ODD and those with ADHD alone did not exhibit differences in measures of attention prior to taking MPH, nor in demographic variables (age, intelligence quotient, gender), clinical characteristics related to symptom severity, and adaptive behaviors. However, we observed differences between the two groups in certain behavioral aspects, including the Dysregulation Profile and disruptive behaviors. Assessing symptoms in combination with the presence of ADHD can be beneficial in determining which individuals would derive the greatest benefits from treatment.

References

Biederman J, Petty C, Doyle A, Spencer T, Henderson C, Marion B . Stability of executive function deficits in girls with ADHD: a prospective longitudinal followup study into adolescence. Dev Neuropsychol. 2008; 33(1):44-61. DOI: 10.1080/87565640701729755. View

Ter-Stepanian M, Grizenko N, Zappitelli M, Joober R . Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders. Can J Psychiatry. 2010; 55(5):305-12. DOI: 10.1177/070674371005500506. View

Noordermeer S, Luman M, Oosterlaan J . A Systematic Review and Meta-analysis of Neuroimaging in Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) Taking Attention-Deficit Hyperactivity Disorder (ADHD) Into Account. Neuropsychol Rev. 2016; 26(1):44-72. PMC: 4762933. DOI: 10.1007/s11065-015-9315-8. View

Guven A, Altinkaynak M, Dolu N, Demirci E, Ozmen S, Izzetoglu M . Effects of Methylphenidate on Reaction Time in Children with Attention Deficit / Hyperactivity Disorder. Noro Psikiyatr Ars. 2019; 56(1):27-31. PMC: 6427077. DOI: 10.29399/npa.22873. View

van Ewijk H, Noordermeer S, Heslenfeld D, Luman M, Hartman C, Hoekstra P . The influence of comorbid oppositional defiant disorder on white matter microstructure in attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2015; 25(7):701-10. PMC: 4932146. DOI: 10.1007/s00787-015-0784-3. View

Lanza H, Drabick D . Family routine moderates the relation between child impulsivity and oppositional defiant disorder symptoms. J Abnorm Child Psychol. 2010; 39(1):83-94. PMC: 3066087. DOI: 10.1007/s10802-010-9447-5. View

Chan M, Leung P, Ho T, Hung S, Lee C, Tang C . Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?. Neuropsychiatr Dis Treat. 2017; 13:1071-1080. PMC: 5396959. DOI: 10.2147/NDT.S128086. View

Marsh A, Finger E, Mitchell D, Reid M, Sims C, Kosson D . Reduced amygdala response to fearful expressions in children and adolescents with callous-unemotional traits and disruptive behavior disorders. Am J Psychiatry. 2008; 165(6):712-20. DOI: 10.1176/appi.ajp.2007.07071145. View

Huss M, Duhan P, Gandhi P, Chen C, Spannhuth C, Kumar V . Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. Neuropsychiatr Dis Treat. 2017; 13:1741-1751. PMC: 5505611. DOI: 10.2147/NDT.S130444. View

10.

Reale L, Bonati M . ADHD prevalence estimates in Italian children and adolescents: a methodological issue. Ital J Pediatr. 2018; 44(1):108. PMC: 6126024. DOI: 10.1186/s13052-018-0545-2. View

11.

Firat S, Gul H, Aysev A . An Open-Label Trial of Methylphenidate Treating Sluggish Cognitive Tempo, Inattention, and Hyperactivity/Impulsivity Symptoms Among 6- to 12-Year-Old ADHD Children: What Are the Predictors of Treatment Response at Home and School?. J Atten Disord. 2020; 25(9):1321-1330. DOI: 10.1177/1087054720902846. View

12.

Masi G, Milone A, Manfredi A, Brovedani P, Pisano S, Muratori P . Combined pharmacotherapy-multimodal psychotherapy in children with Disruptive Behavior Disorders. Psychiatry Res. 2016; 238:8-13. DOI: 10.1016/j.psychres.2016.02.010. View

13.

Sergeant J, Geurts H, Huijbregts S, Scheres A, Oosterlaan J . The top and the bottom of ADHD: a neuropsychological perspective. Neurosci Biobehav Rev. 2003; 27(7):583-92. DOI: 10.1016/j.neubiorev.2003.08.004. View

14.

Meyer S, Carlson G, Youngstrom E, Ronsaville D, Martinez P, Gold P . Long-term outcomes of youth who manifested the CBCL-Pediatric Bipolar Disorder phenotype during childhood and/or adolescence. J Affect Disord. 2008; 113(3):227-35. DOI: 10.1016/j.jad.2008.05.024. View

15.

Masi G, Fantozzi P, Muratori P, Bertolucci G, Tacchi A, Villafranca A . Emotional dysregulation and callous unemotional traits as possible predictors of short-term response to methylphenidate monotherapy in drug-naïve youth with ADHD. Compr Psychiatry. 2020; 100:152178. DOI: 10.1016/j.comppsych.2020.152178. View

16.

Hodgkins P, Shaw M, Coghill D, Hechtman L . Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012; 21(9):477-92. PMC: 3432777. DOI: 10.1007/s00787-012-0286-5. View

17.

Faraone S, Buitelaar J . Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2009; 19(4):353-64. DOI: 10.1007/s00787-009-0054-3. View

18.

Matthys W, Vanderschuren L, Schutter D, Lochman J . Impaired neurocognitive functions affect social learning processes in oppositional defiant disorder and conduct disorder: implications for interventions. Clin Child Fam Psychol Rev. 2012; 15(3):234-46. DOI: 10.1007/s10567-012-0118-7. View

19.

Carpentier P, Levin F . Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?. Harv Rev Psychiatry. 2017; 25(2):50-64. PMC: 5518741. DOI: 10.1097/HRP.0000000000000122. View

20.

Connor D, Findling R, Kollins S, Sallee F, Lopez F, Lyne A . Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010; 24(9):755-68. DOI: 10.2165/11537790-000000000-00000. View